ArticleAntimicrobial agents and chemotherapy1997
Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- An inhalable dry powder co-delivery system of ciprofloxacin liposomes and S-nitrosoglutathione for synergistic treatment of Pseudomonas aeruginosa biofilm-associated pulmonary infections.Drug delivery and translational research · 2026Article
- Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery.Heliyon · 2022Review
- Article
- Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis.Frontiers in pharmacology · 2020Review
- Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.Frontiers in microbiology · 2017Article
- Development of Liposomal Ciprofloxacin to Treat Lung Infections.Pharmaceutics · 2016Review
- Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Clinical microbiology reviews · 2014Review
- Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.Antimicrobial agents and chemotherapy · 2014Article
- Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.Antimicrobial agents and chemotherapy · 2014Article
- The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.Frontiers in cellular and infection microbiology · 2014Review
- New therapeutic approaches for treatment of tularaemia: a review.Frontiers in cellular and infection microbiology · 2014Review
- Niosomes of ascorbic acid and α-tocopherol in the cerebral ischemia-reperfusion model in male rats.BioMed research international · 2014Article
- Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.Antimicrobial agents and chemotherapy · 2013Article
- The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.Pharmaceutical research · 2011Article
- Antimicrobial activity and mechanism of action of Nu-3, a protonated modified nucleotide.Annals of clinical microbiology and antimicrobials · 2011Article
- Nanotechnology: intelligent design to treat complex disease.Pharmaceutical research · 2006Review
- Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.British journal of clinical pharmacology · 2003Review
- Tularemia.Clinical microbiology reviews · 2002Review
- Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.Antimicrobial agents and chemotherapy · 2002Article
- Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Antimicrobial agents and chemotherapy · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aerosol delivery of liposome-encapsulated ciprofloxacin by using 12 commercially available jet nebulizers was evaluated in this study. Aerosol particles containing liposome-encapsulated ciprofloxacin generated by the nebulizers were analyzed with a laser aerodynamic particle sizer. Mean mass aerodynamic diameters (MMADs) and geometric standard deviations (GSDs) were determined, and the drug contents of the sampling filters from each run onto which aerosolized liposome-encapsulated ciprofloxacin had been deposited were analyzed spectrophotometrically. The aerosol particles of liposome-encapsulated ciprofloxacin generated by these nebulizers ranged from 1.94 to 3.5 microm, with GSDs ranging from 1.51 to 1.84 microm. The drug contents of the sampling filters exposed for 1 min to aerosolized liposome-encapsulated ciprofloxacin range from 12.7 to 40.5 microg/ml (0.06 to 0.2 mg/filter). By using the nebulizer selected on the basis of most desirable MMADs, particle counts, and drug deposition, aerosolized liposome-encapsulated ciprofloxacin was used for the treatment of mice infected with 10 times the 50% lethal dose of Francisella tularensis. All mice treated with aerosolized liposome-encapsulated ciprofloxacin survived the infection, while all ciprofloxacin-treated or untreated control mice succumbed to the infection (P < 0.001). These results suggest that aerosol delivery of liposome-encapsulated ciprofloxacin to the lower respiratory tract is feasible and that it may provide an effective therapy for the treatment of respiratory tract infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.